Turnstone Biologics, Corp. clinical trials
Acquired by Ligand Pharmaceuticals Incorporated, Jul 14, 2026 · source ↗
The registry lists 5 studies whose lead sponsor is Turnstone Biologics, Corp.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 23, 2025.
Before and after it joined Ligand Pharmaceuticals Incorporated
- First submitted before Turnstone Biologics, Corp. became part of Ligand Pharmaceuticals Incorporated
- 5
- First submitted after Turnstone Biologics, Corp. became part of Ligand Pharmaceuticals Incorporated
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Turnstone Biologics, Corp.5 studies
Something wrong with this grouping? Tell us on the Ligand Pharmaceuticals Incorporated page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Ligand Pharmaceuticals Incorporated studies →
- Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid TumorsTerminatedNCT04301011Phase 1
Sponsor listed in the registry: Turnstone Biologics, Corp. · First submitted before Turnstone Biologics, Corp. became part of Ligand Pharmaceuticals Incorporated
- A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid TumorsTerminatedNCT05576077Phase 1
Sponsor listed in the registry: Turnstone Biologics, Corp. · First submitted before Turnstone Biologics, Corp. became part of Ligand Pharmaceuticals Incorporated
- This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated CancersTerminatedNCT03618953Phase 1
Sponsor listed in the registry: Turnstone Biologics, Corp. · First submitted before Turnstone Biologics, Corp. became part of Ligand Pharmaceuticals Incorporated
- MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell CarcinomaWithdrawnNCT03773744Phase 1
Sponsor listed in the registry: Turnstone Biologics, Corp. · First submitted before Turnstone Biologics, Corp. became part of Ligand Pharmaceuticals Incorporated
- Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer PatientsCompletedNCT02879760Phase 1/2
Sponsor listed in the registry: Turnstone Biologics, Corp. · First submitted before Turnstone Biologics, Corp. became part of Ligand Pharmaceuticals Incorporated